Looks good, considering buying soon. Yet another biotech getting unfairly battered due to overall sentiment when there is nothing wrong with the company. Quite undervalued IMO. Merck's competitor cholesterol drug seems to be on par (and is actually validated in humans), so NYR is behind, but in such a huge space, there may be enough room for more than one player. Even if it is not first to market, clinical progression of the asset should warrant a much higher MC than $33m AUD regardless.
IMO.
Ann: Investor Roadshow Presentation, page-2
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
